{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:32:30Z","timestamp":1715905950453},"reference-count":26,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2024.14381","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T11:42:57Z","timestamp":1712144577000},"source":"Crossref","is-referenced-by-count":0,"title":["Daratumumab\u2011resistant multiple myeloma with extramedullary disease successfully treated with combination elotuzumab, pomalidomide and dexamethasone: A case report"],"prefix":"10.3892","volume":"27","author":[{"given":"Masataka","family":"Sakashita","sequence":"first","affiliation":[{"name":"Department of Hematology, Kanto Rosai Hospital, Kawasaki, Kanagawa 211\u20110021, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohi","family":"Sahara","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kanto Rosai Hospital, Kawasaki, Kanagawa 211\u20110021, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Aoki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kanto Rosai Hospital, Kawasaki, Kanagawa 211\u20110021, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Matsunaga","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kanto Rosai Hospital, Kawasaki, Kanagawa 211\u20110021, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichiro","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kanto Rosai Hospital, Kawasaki, Kanagawa 211\u20110021, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Kitahara","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kanto Rosai Hospital, Kawasaki, Kanagawa 211\u20110021, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kanto Rosai Hospital, Kawasaki, Kanagawa 211\u20110021, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Ohno","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kanto Rosai Hospital, Kawasaki, Kanagawa 211\u20110021, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2024,4,3]]},"reference":[{"key":"key20240516111747_b1-ol-27-6-14381","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: A systematic literature review","volume":"12","author":"Blad\u00e9","year":"2022","journal-title":"Blood Cancer J"},{"key":"key20240516111747_b2-ol-27-6-14381","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/EDBK_205443","article-title":"Practical considerations for antibodies in myeloma","volume":"38","author":"Laubach","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"key20240516111747_b3-ol-27-6-14381","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"24","author":"Casneuf","year":"2017","journal-title":"Blood Adv"},{"key":"key20240516111747_b4-ol-27-6-14381","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"His","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key20240516111747_b5-ol-27-6-14381","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"key":"key20240516111747_b6-ol-27-6-14381","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/10428194.2019.1688324","article-title":"Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma","volume":"61","author":"Hoylman","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"key20240516111747_b7-ol-27-6-14381","doi-asserted-by":"publisher","first-page":"5159","DOI":"10.1038\/s41598-023-32426-6","article-title":"Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa\/lambda ratio or B2 microglobulin","volume":"13","author":"Shimazu","year":"2023","journal-title":"Sci Rep"},{"key":"key20240516111747_b8-ol-27-6-14381","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for multiple myeloma: A report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20240516111747_b9-ol-27-6-14381","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"key20240516111747_b10-ol-27-6-14381","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"key20240516111747_b11-ol-27-6-14381","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"key":"key20240516111747_b12-ol-27-6-14381","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/ejh.12826","article-title":"Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma","volume":"98","author":"Badar","year":"2017","journal-title":"Eur J Haematol"},{"key":"key20240516111747_b13-ol-27-6-14381","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00277-012-1414-5","article-title":"Features of extramedullary myeloma relapse: High proliferation, minimal marrow involvement, adverse cytogenetics: A retrospective single-center study of 24 cases","volume":"91","author":"Rasche","year":"2012","journal-title":"Ann Hematol"},{"key":"key20240516111747_b14-ol-27-6-14381","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1007\/s00277-021-04447-6","article-title":"Elotuzumab for the treatment of extramedullary myeloma: A retrospective analysis of clinical efficacy and SLAMF7 expression patterns","volume":"100","author":"Danhof","year":"2021","journal-title":"Ann Hematol"},{"key":"key20240516111747_b15-ol-27-6-14381","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"key20240516111747_b16-ol-27-6-14381","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"key20240516111747_b17-ol-27-6-14381","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1200\/JCO.22.00940","article-title":"Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): A randomized, open-label, phase III trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"key":"key20240516111747_b18-ol-27-6-14381","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1200\/JCO.21.02734","article-title":"Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): A randomized, open-label, phase III trial","volume":"41","author":"Sonneveld","year":"2023","journal-title":"J Clin Oncol"},{"key":"key20240516111747_b19-ol-27-6-14381","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"key20240516111747_b20-ol-27-6-14381","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): A randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"key":"key20240516111747_b21-ol-27-6-14381","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"key20240516111747_b22-ol-27-6-14381","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): Overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"key":"key20240516111747_b23-ol-27-6-14381","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00432-018-2807-1","article-title":"Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy","volume":"145","author":"Danhof","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"key20240516111747_b24-ol-27-6-14381","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1038\/s41423-021-00686-9","article-title":"Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model","volume":"18","author":"Thangaraj","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"key20240516111747_b25-ol-27-6-14381","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1158\/1535-7163.MCT-17-0998","article-title":"Antibody-dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab","volume":"17","author":"Kurdi","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"key20240516111747_b26-ol-27-6-14381","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1200\/JCO.21.02815","article-title":"Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: Final overall survival analysis from the randomized phase II ELOQUENT-3 trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T08:18:45Z","timestamp":1715847525000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2024.14381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,3]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,4,3]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2024.14381","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,3]]},"article-number":"248"}}